The severe revenue decline and EPS miss will pressure the stock near-term, but the VEPPANU approval and Rigel out-licensing provide a long-term floor. Watch for HSR clearance on the Rigel deal and upcoming pipeline catalysts (ARV-102 PSP trial initiation, ARV-806 initial data) in 2H 2026. The cash runway into 2H 2028 reduces near-term dilution risk.
ARVN drugs
ARVN drug pipeline →How the stock moved after the report
⚠ Clustered BEARISH VIEWSTOCK BELOW ENTRY AT T+60- T+0 · May 12 $9.57entry
- T+1 · 6mo ago +3.13%α +2.56% · $9.87
- T+5 · 6mo ago −8.26%α −8.33% · $8.78
- T+20 · 5mo ago −27.06%α −25.34% · $6.98
- T+60 · 3mo ago −9.30%α −13.68% · $8.68
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Arvinas reported Q1 2026 revenue of $15.6M (down 91.7% YoY from $188.8M) and a GAAP EPS of -$0.90, significantly missing the consensus estimate of -$0.63. The revenue collapse was driven by the removal of two Phase 3 trials from the Pfizer collaboration plan, which had inflated prior-year revenue. While the FDA approval of VEPPANU (first-ever PROTAC) and its out-licensing to Rigel are transformative milestones, the severe revenue decline and EPS miss dominate the near-term narrative.
Key Financial Metrics
Key Facts
- Q1 2026 revenue of $15.6M vs $188.8M YoY, a 91.7% decline due to changes in Pfizer collaboration cost estimates
- GAAP EPS of -$0.90 vs consensus -$0.63, a 42.9% miss
- Cash burn of $67.5M in operations during Q1; cash position $614.9M, sufficient into 2H 2028
- FDA approval of VEPPANU (vepdegestrant) as first-ever PROTAC therapy for ER+/HER2- breast cancer
- Out-licensing of VEPPANU to Rigel Pharmaceuticals for exclusive global rights (closing pending HSR review)
- R&D expenses fell 33.6% YoY to $60.3M, driven by reduced vepdegestrant program costs
- Pipeline progress: ARV-102 Phase 1 biomarker data, ARV-806 dose escalation completed, ARV-393 combo trial initiated
Financial Impact
Revenue collapsed 91.7% YoY to $15.6M; EPS miss of 42.9% vs consensus; operating cash burn of $67.5M in Q1
Risk Factors
- Revenue collapse driven by Pfizer collaboration changes may signal further partnership uncertainty
- VEPPANU commercial success depends on Rigel's execution and market adoption post-approval
- Pipeline setbacks in ARV-102, ARV-806, or ARV-393 could impair valuation given thin revenue base
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3292695 |
Track record
21 reports on ARVN
6 of 8 bullish or bearish reports moved the stock their way by T+1. Best: +28.62% at T+60 after the Feb 23, 2026 report. 8 of 8 went positive at some point.
Filters
- Nov 3, 202613d ago S-3 Bearish 5/10 Entry $7.42 to $6.55 Now $6.77 +8.76% ▲ +11.73% +7.32% vs SPY
- Nov 3, 202613d ago 8-K Bearish 5/10 No price data
- Nov 3, 202613d ago Press Release Neutral 4/10 Entry $7.09 to $7.42 Now $6.77 −4.51% ▲ +4.65% +3.00% vs SPY
- Sep 4, 202610w ago 144 Neutral 3/10 Entry $9.08 to $8.76 Now $6.77 −25.44% ▼ −3.52% −3.06% vs SPY
- Jun 22, 202621w ago 8-K Neutral 3/10 Entry $8.14 to $8.05 Now $6.77 −16.83% ▼ −1.11% −1.06% vs SPY
- Jun 2, 202623w ago 8-K Bearish 6/10 Entry $7.70 to $7.74 Now $6.77 +12.08% ▼ −0.52% −0.12% vs SPY
- May 12, 202626w ago 8-K Mixed 6/10 No price data
- May 12, 202626w ago 8-K Bullish 7/10 Entry $9.57 to $9.87 Now $6.77 −29.26% ▲ +3.13% +2.56% vs SPY
- May 12, 202626w ago Press Release Bearish 8/10 Viewing Entry $9.57 to $9.87 Now $6.77 +29.26% ▼ −3.13% −2.56% vs SPY
- May 8, 202627w ago 144 Neutral 2/10 Entry $9.66 to $9.57 Now $6.77 −29.92% ▼ −0.93% −0.80% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers